Pueraria lobata

PreclinicalSmall molecule

JJiangxi University of Traditional Chinese Medicine

Pueraria lobata is one of 50 small molecule programs targeting Dyslipidemia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DyslipidemiaCompleted

Type 2 Diabetes MellitusActive, not recruiting

DyslipidemiaPreclinical

Completed

Type 2 Diabetes MellitusPreclinical

Active, not recruiting

Competition

Competitive Landscape

150 competitors in Type 2 Diabetes Mellitus

#DrugCompanyPhaseTrials

Retatrutide

Eli Lilly

Phase 3

1 2

Enavogliflozin

Daewoong Pharmaceutical Co. LTD.

Phase 3

1 3

GZR18

GGan & Lee Pharmaceuticals.

Phase 3

5 4

GZR4

GGan and Lee Pharmaceuticals, USA

Phase 3

5 5

Ganagliflozin

HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Phase 3

1 6

Imeglimin

PPoxel SA

Phase 3

1 7

HM11260C

Hanmi Pharmaceutical Company Limited

Phase 3

3 8

Dorzagliatin

HHua Medicine Limited

Adenocard

1 10

NOVOLIN R

Novo Nordisk

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Dyslipidemia1 trial

Pueraria Lobata and Pueraria Thomsonii for Mild Dyslipidemia

Completed·JJiangxi University of Traditional Chinese Medicine·N/A·NCT04861376·174 enrolled

Type 2 Diabetes Mellitus1 trial

Efficacy and Safety of Pueraria Lobata Radix As an Adjuvant Treatment for Type 2 Diabetes Mellitus

Recruiting·JJiangxi University of Traditional Chinese Medicine·N/A·NCT06494683·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Pueraria lobata. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pueraria lobata compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pueraria lobata. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangxi University of Traditional Chinese Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: JJiangxi University of Traditional Chinese Medicine

Pueraria lobata

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Dyslipidemia1 trial

Type 2 Diabetes Mellitus1 trial

References

Drug Info

Quick Facts

Related News